| A326 |
U.Texas patent anti-LILRB4 Biosimilar（Anti-LILRB4 / ILT3 / CD85k Reference Antibody）
Featured
|
|
|
| A327 |
Opicinumab Biosimilar（Anti-LINGO1 Reference Antibody）
Featured
|
Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis. |
|
| A328 |
Ladiratuzumab Biosimilar（Anti-LIV-1 / SLC39A6 Reference Antibody）
Featured
|
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer. |
|
| DC66951 |
Aflatoxin M2
Featured
|
Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2. |
|
| A329 |
Simtuzumab Biosimilar（Anti-LOXL2 Reference Antibody）
Featured
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC). |
|
| A330 |
RG7841 Biosimilar（Anti-Ly6E Reference Antibody）
Featured
|
|
|
| A331 |
MEN1309 Biosimilar（Anti-LY75 / CD205/DEC-205 Reference Antibody）
Featured
|
|
|
| A332 |
CDX-1401 Biosimilar(Anti-LY75 / CD205/DEC-205 Reference Antibody)
Featured
|
|
|
| A333 |
Ontamalimab Biosimilar(Anti-MADCAM1 Reference Antibody)
Featured
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease. |
|
| A334 |
CT Atlantic patent anti-MAGE-A3 Biosimilar(Anti-MAGEA3 Reference Antibody)
Featured
|
|
|
| A335 |
IMC-C103C Biosimilar(Anti-MAGE-A4 Reference Antibody)
Featured
|
|
|
| A336 |
Narsoplimab Biosimilar(Anti-MASP2 Reference Antibody)
Featured
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2. |
|
| A337 |
Oxford Bio patent anti-Matriptase Biosimilar(Anti-Matriptase Reference Antibody)
Featured
|
|
|
| A338 |
Tokai U. Patent Anti-Meflin Biosimilar(Anti-Meflin Reference Antibody)
Featured
|
|
|
| A339 |
SC-005 Biosimilar(Anti-Melanotransferrin / CD228 Reference Antibody)
Featured
|
|
|
| A340 |
RGX-019 Biosimilar(Anti-MER / MERTK Reference Antibody)
Featured
|
|
|
| A341 |
Amatuximab Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium. |
|
| A342 |
BMS-986148 Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
|
|
| A343 |
Anetumab Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
|
| A344 |
NIH patent anti-Mesothelin Biosimilar(Anti-Mesothelin Reference Antibody)
Featured
|
|
|
| A345 |
CLN-619 Biosimilar(Anti-MICA Reference Antibody)
Featured
|
|
|
| A346 |
U.Washington patent anti-MICB Biosimilar(Anti-MICB Reference Antibody )
Featured
|
|
|
| A347 |
Imalumab Biosimilar(Anti-MIF Reference Antibody)
Featured
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer. |
|
| A348 |
Andecaliximab Biosimilar(Anti-MMP9 Reference Antibody)
Featured
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). |
|
| A349 |
Yeda patent anti-MMP-9 Biosimilar(Anti-MMP9 Reference Antibody)
Featured
|
|
|
| A350 |
TA136 Biosimilar(Anti-MPL / TPOR / CD110 Reference Antibody)
Featured
|
|
|
| A351 |
Copenhagen Rigshospitalet patent anti-uPARAP Biosimilar(Anti-MRC2 / CD280 Reference Antibody)
Featured
|
|
|
| A352 |
Quark patent anti-ENDO 180 Biosimilar（Anti-MRC2 / CD280 Reference Antibody）
Featured
|
|
|
| A353 |
Narnatumab Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer. |
|
| A354 |
Aveo anti-RON Biosimilar（Anti-MSPR / RON / CD136 Reference Antibody）
Featured
|
|
|
